References
- Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol 2019;51:72-80.
- Jean SS, Harnod D, Hsueh PR. Global threat of carbapenem-resistant Gramnegative bacteria. Front Cell Infect Microbiol 2022;12:823684.
- Skaar EP, Echols R, Matsunaga Y, Menon A, Portsmouth S. Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study. Eur J Clin Microbiol Infect Dis 2022;41(3):467-76.
- Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2018;18(12):1319-28.
- Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2021;21(2):213-25.
- Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogenfocused, descriptive, phase 3 trial. Lancet Infect Dis 2021;21(2):226-40.
- Timsit JF, Paul M, Shields RK, Echols R, Baba T, Yamano Y, et al. Cefiderocol for the treatment of infections due to metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies. Clin Infect Dis 2022;75(6):1081-4.
- Hung KC, Tsai WW, Hsu C, Lai CC, Tang HJ, Chen IW. Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: A systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents 2023;62(1):106830.
- Lin MH, Shen YC, Cheng HY, Teng CK, Chen WC, Lin YC, et al. Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: A network meta-analysis of randomised clinical trials. J Glob Antimicrob Resist 2023;34:46-58.
- Hsueh SC, Chao CM, Wang CY, Lai CC, Chen CH. Clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomised controlled trials. J Glob Antimicrob Resist 2021;24:376-82.
- Gatti M, Cosentino F, Giannella M, Viale P, Pea F. Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis. Int J Antimicrob Agents 2024;63(2):107047.
- Nordmann P, Shields RK, Doi Y, Takemura M, Echols R, Matsunaga Y, et al. Mechanisms of reduced susceptibility to cefiderocol among isolates from the CREDIBLE-CR and APEKS-NP clinical trials. Microb Drug Resis 2022;28(4):398-407.
- Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis EI. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. Clin Microbiol Infect 2024;30(2):178-88.
- Sanabria C, Migoya E, Mason JW, Stanworth SH, Katsube T, Machida M, et al. Effect of cefiderocol, a siderophore cephalosporin, on QT/QTc interval in healthy adult subjects. Clin Ther 2019;41(9):1724-36.e4.
- Katsube T, Miyazaki S, Narukawa Y, Hernandez-Illas M, Wajima T. Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters. Eur J Clin Pharmacol 2018;74(7):931-8.
- Naseer S, Weinstein EA, Rubin DB, Suvarna K, Wei X, Higgins K, et al. US Food and Drug Administration (FDA): benefit-risk considerations for cefiderocol (Fetroja®). Clin Infect Dis 2021;72(12):e1103-11.
- CHMP. Annex I. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/fetcroja-epar-productinformation_en.pdf (6.04.2025).
- Clancy CJ, Cornely OA, Slover CM, Nguyen ST, Kung FH, Verardi S, et al. Real-world effectiveness and safety of cefiderocol in the treatment of patients with serious Gram-negative bacterial infections: Results of the PROVE chart review study. Open Forum Infect Dis 2025;12(Suppl 1):ofae631.1645.
- Ramirez P, Merino E, Sarda J, Gonzalez AJ, Verardi S, Fortun J. Real-world effectiveness and safety of cefiderocol in patients with Gram-negative bacterial infections in the early access programme in Spain: results of the PERSEUS study. Barcelona: ESCMID Global 2024;2024. Poster 2523.
- Huang M, Cai F, Liu C, Zheng H, Lin X, Li Y, et al. Effectiveness of novel β-lactams for Pseudomonas aeruginosa infection: A systematic review and meta-analysis. Am J Infect Control 2024;52(7):774-84.
- Onorato L, de Luca I, Monari C, Coppola N. Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis. J Infect 2024;88(3):106113.